TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of invasive bladder cancer~* Must be confirmed by chest and abdominal CT scan OR pelvic MRI scan and transurethral biopsy (with definitive muscle invasion \> T2) within 4 weeks prior to registration~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* WBC ≥ 3,000/mm\^3~* Neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Total bilirubin ≤ 1.5 mg/dL~* Serum creatinine ≤ 1.5 mg/dL~* AST and ALT ≤ 2.5 x upper limit of normal~* Not pregnant~* No liver cirrhosis~* No ischemic cardiovascular disease or arrhythmia for which treatment is necessary~* No cardiac infarction within the past 6 months~* No interstitial pneumonia, pulmonary fibrosis, or any other diseases by which oxygen inhalation therapy is needed~* No active cancerous lesion other than upper urinary tract tumor~* No high fever or any other infectious symptom~* No uncontrolled hypertension or diabetes mellitus~PRIOR CONCURRENT THERAPY:~* No prior systemic chemotherapy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Acute and Subacute Effects of Nicotine Free Electronic Cigarette(NCFE) Vapors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~INCLUSION CRITERIA:~* Subjects will be over 18 years of age.~* Healthy life-time non-smokers~Exclusion Criteria:~* Presence of airflow obstruction (COPD, asthma, bronchiectasis)~* Other concomitant inflammatory pulmonary disorders~* Subjects with known pulmonary malignancies within 5 years~* Subjects with prior thoracic surgery~* Subjects with respiratory infection that required use of oral corticosteroids and/or antibiotics within the prior 3 months~* Subjects with allergies to study medications~* Subjects incapable of providing informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- vape NFEC containing 100% PG (Type: EXPERIMENTAL): Subjects will then be instructed how to use the NFEC (eGo-T® with light emitting diode (LED) display) for 1 week of regularly vaping NFEC containing 100% Propylene Glycol . Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 mAh battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to \~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
- vape 100% vegetable glycerin -VG (Type: EXPERIMENTAL): Subjects will then be instructed how to use the NFEC (eGo-T® with LED display) for 1 week of regularly vaping NFEC containing 100% VG. Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 mAh battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to \~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
- vape PG+VG (Type: EXPERIMENTAL): Subjects will then be instructed how to use the NFEC (eGo-T® with LED display) for 1 week of regularly vaping NFEC containing 50% PG and 50% VG. Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 milliamp hours (mAh) battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to \~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of gastric adenocarcinoma.~* Clinical stage cT2 or higher.~* No evidence of metastatic disease on preoperative imaging.~* Patient fit for surgery (ECOG 0 or 1).~Exclusion Criteria:~* Indocyanine allergy.~* Gastric cancer subtype other than gastric adenocarcinoma.~* Unconfirmed diagnosis of gastric adenocarcinoma (unable to confirm diagnosis).~* Clinical stage cT1b or lower.~* Evidence of metastatic disease on preoperative imaging.~* Patient unfit for surgery (ECOG 2 or more).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Gastric cancer with ICG (Type: EXPERIMENTAL): Patient to receive IV ICG during diagnostic laparoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proper Fractional Flow Reserve Criteria for Intermediate Lesions in the Era of Drug-eluting Stent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective PCI~* Angiographically intermediate stenosis (50-75% by visual estimation) in native major coronary arteries, proximal and mid (branch, distal lesion: exclusion)~* Reference diameter \> 2.5mm, lesion length \< 60mm (cover by 2 stents)~* No documented evidence of ischemia by noninvasive tests~Exclusion Criteria:~* Acute ST elevation MI~* Left main disease~* Chronic renal failure (cr \>2 mg/dL)~* Expected survival \< 2yrs~* \> 1degree AV block

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Fractional flow guided drug-eluting stent implantation arm
- 2 (Type: OTHER): Routine drug-eluting stent implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of HMB Supplementation on Adipose Tissue Inflammation and Metabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Non-smoker~* Body mass index of 35-40 kg/m2~* Age 18-40 years~* Weight stable for past 6 months (\<5 lb. change)~* In good health, free of chronic diseases/conditions that may impact measured outcomes~* Willing and able to consume a weight loss diet~* Willing and able to consume a daily nutritional supplement (in pill form)~* Available for scheduled study commitments during the 2 months of study~Exclusion Criteria:~* Smoke~* Take any cholesterol lowering or weight loss drugs or an drugs or supplements that affect blood lipids, insulin or body composition~* Weigh greater 300 pounds due to weight, size and depth limitations of equipment~* Take dietary supplements~* Have a chronic disease such as:~* Cardiopulmonary disease (e.g. recent myocardial infarction, unstable angina, stroke) or unstable disease~* Severe orthopedic/musculoskeletal or neuromuscular impairments that would contradict exercise~* Sensory impairments that interfere with following directions~* Diagnosis if dementia~* History of malignancy during the past 5 years~* Diabetes mellitus

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Placebo Diet Restriction (Type: PLACEBO_COMPARATOR): None
- Placebo No Diet Restriction (Type: PLACEBO_COMPARATOR): None
- HMB Diet Restriction (Type: ACTIVE_COMPARATOR): None
- HMB No Diet Restriction (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-breast feeding female ≥ 18 years old~* In remission from demonstrated overt HE~* Had ≥1 episode of overt HE associated with liver disease within the last 6 months~* MELD score of ≥ 19~* Has a close family member or other personal contact who is familiar with the subject's HE, can provide continuing oversight to the subject and is willing to be available to the subject during the conduct of the trial~Exclusion Criteria:~* HIV~* History of tuberculosis infection~* Chronic respiratory insufficiency~* Current infection and receiving antibiotics~* Renal insufficiency requiring dialysis~* Active spontaneous bacterial peritonitis infection~* Intestinal obstruction or has inflammatory bowel disease~* Active malignancy within the last 5 years~* Current GI bleeding or has had a GI hemorrhage within past 3 months~* Anemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rifaximin (Type: EXPERIMENTAL): Rifaximin, oral, 550 mg BID, 6 months of treatment
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, oral, 0 mg BID, 6 months of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* A positive test for SARS-CoV-2~* A GP consultation for deteriorating COVID-19 symptoms~Additional inclusion criteria in order to be eligible for randomization to the trial:~- Exercise-induced desaturation, defined as SpO2\<92% (\<90% for COPD patients) and/or an absolute drop of ≥4% in SpO2 after a 1-minute sit-to-stand test~OR~- SpO2\<92% (\<90% for COPD patients) in rest with GP's and patient's shared decision to keep patient at home despite this in itself being an indication for referral to hospital~Exclusion Criteria:~* Inability to understand and sign the written consent form~* Inability to perform saturation measurements or sit-to-stand test~* Not willing to be admitted to hospital~* On the discretion of the recruiting clinician if he or she deems a patient not eligible~The following criterion will be used to exclude patients from randomization to the trial:~* Contra-indication for dexamethasone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): 6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
- Control (Type: NO_INTERVENTION): Only remote monitoring

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anabolic Steroids for Nutritional Rehabilitation of Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. anticipated length of stay in ICU \>10 days~2. moderate to severe malnutrition~3. patient tolerating enteral feeds~Exclusion Criteria:~1. age \< 18 yrs~2. known allergy to nandrolone~3. women of child bearing age with positive pregnancy test~4. contraindications to intramuscular injections ie anticoagulation~5. renal failure requiring renal replacement therapy~6. patients with breast or prostate cancer -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- nandrolone (Type: EXPERIMENTAL): Patients receive weekly injections of nandrolone
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effectiveness of an Activity-specific Monitoring Device- StepRite

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral partial or total knee arthroplasty.~* Age 45-75 yr. old~* BMI \<35~* Access to Wi-Fi~* Have appropriate smart phone and knowledge of use~* Be willing to place StepRite app on their personal phone~Exclusion Criteria:~* History of neuromuscular disorder (e.g. Parkinson's, Polio, or stroke).~* Pregnancy~* History of cognitive disease that would preclude ability to navigate smart phone

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Active Comparator Steprite™ Device' (Type: ACTIVE_COMPARATOR): steprite™ device active Comparator- The steprite™ System is a monitoring and biofeedback system for the Monitoring of rehabilitation patients Measuring pressure distribution, gait and range of motion of the lower extremities while a patient performs specified rehabilitation exercises
- Control (Type: PLACEBO_COMPARATOR): Control outcomes with no device. Standard of care physical therapy and outcomes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for elective hysterectomy at Mayo Clinic in Arizona~* ASA I, II, or III~Exclusion Criteria:~* Pregnancy~* Concomitant bowel surgery other than appendectomy~* Hypersensitivity to study drug or rescue medication~* Preoperative score for nausea greater than 4 out of 10 points~* Severe hepatic insufficiency (Child-Pugh score \> 9)~* Any condition which impairs the patient's ability to complete study assessments~* Intraoperative hemodynamic instability~* ICU admission~* Prolonged postoperative intubation~* Rifampin, carbamazepine, phenytoin, or other drugs which strongly induce CYP3A4 activity~* Other antiemetic within 12 hours prior to surgery~* Participation in a clinical trial using an investigational product

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aprepitant (Type: EXPERIMENTAL): 40 mg aprepitant
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Periurethral Pro-ACTTM Balloons vs Retrourethral AdvanceXP(TM) Male Sling for Post-prostatectomy Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Patient presenting mild to moderate stress urinary incontinence (20g \< 72 hours pad-test \< 300g) following radical prostatectomy more than 1 year ago.~* Patient capable of roaming, independent and capable of using toilet without any trouble.~* Patients able to answer to questionnaire and communicate in French~* Informed consent~* Patients with social security~Exclusion Criteria:~* Uncontrolled prostatic adenocarcinoma or PSA \> 1 ng/ml~* Maximum urinary flow rate \< 15 ml/sec~* Postvoid residual volume \> 150 ml~* Urinated volume in 24h \> 3000 ml~* Uninhibited detrusor contractions associated with leakage during the preoperative urodynamic assessment (realized under anticholinergic if the patient is usually under this medication)~* Severe incontinence (Pad test \> 300g/24h)~* History of artificial urinary sphincter~* Known neurologic bladder dysfunction~* History of neurological disease which can interfere with the urinary symptoms~* Presence of a urethral stenosis or of an anastomotic stricture during the preoperative endoscopy.~* Previous treatment with pelvic radiation therapy in 6 months before inclusion~* Uncontrolled urinary tract infection~* Patients affected by an infiltrative bladder tumour~* Patients with bladder stones~* Severe constitutional hemorrhagic disease or haemophilia~* Deep depression of immune system~* Severe renal impairment or obstructive pathology of the upper urinary tract with severe renal impairment

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Patients will receive AdvanceXP retrourethral male sling implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route
- Active comparator (Type: ACTIVE_COMPARATOR): Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Prospective, Multicenter Study for the Role of Primary Tumor Resection in Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age : between 20 and 90 years old~* Histologically confirmed adenocarcinoma of the colon or the upper rectum~* Patients with resectable primary colon or upper rectal cancer and unresectable metastatic lesions.~* Patients with no primary cancer related symptoms.~* ECOG performance status of 0 - 2~* Appropriate organ functions (hepatic transaminases - less than 5 times the normal range; bilirubin - less than 2 times the normal range; creatinine serum - less than 1.5 times the normal range; thrombocyte - more than 100,000/µl; neutrophil - more than 1,500/µl)~* ASA score of \< 3~* An informed consent form has been signed by the patient.~Exclusion Criteria:~* The patient received adjuvant chemotherapy within the past 6 months.~* The patient received chemotherapy for metastatic colon cancer.~* The patient was planning to have curative surgery for the metastatic lesions.~* The primary cancer is unresectable.~* Patients with peritoneal carcinomatosis.~* Patients with mid and low rectal cancer (\< 10cm)~* Patients with primary tumor related complications such as intestinal obstruction, intractable bleeding, and perforation, that needs to be treated.~* ASA score of \> 4~* The patient has chronic hepatitis or cirrhosis. An asymptomatic HBV or HCV carrier can participate.~* Patients with an active infection, which need antibiotic therapy, during the randomization period.~* Pregnant or breastfeeding women~* Patients who were enrolled in another clinical trial during the time of enrollment (within the 28 day randomization period).~* Patients with another different malignant tumor during the past 5 years. Patients with treated non-melanoma skin cancer or cervical cancer can be enrolled in this study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Chemotherapy first without primary tumor resection (Type: EXPERIMENTAL): Patients will receive chemotherapy first without primary tumor resection.
- Primary tumor resection followed by chemotherapy (Type: ACTIVE_COMPARATOR): Patients will receive primary tumor resection followed by chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues